Objectives: Mucormycosis is a rare but refractory mycosis with high mortality. Few therapeutic options are available and novel strategies are needed. Calcineurin inhibitors are known to have antifungal activity, including synergy with various antifungals. We examined the interaction of caspofungin with calcineurin inhibitors and sirolimus against Glomeromycetes.
Introduction
Mucormycosis generally occurs as an opportunistic infection in immunocompromised hosts. Patients who are neutropenic, severely malnourished or immunosuppressed or have diabetic ketoacidosis are especially at risk, and normal individuals may rarely develop the disease. 1 The disease usually manifests with rhinocerebral and pulmonary disease, but cutaneous and gastrointestinal manifestations are also not uncommon. Standard therapy has been high-dose amphotericin B (usually lipid formulations) and surgical debridement where possible, though morbidity and mortality rates are high, especially in immunocompromised patients. 2 The significant toxicities of amphotericin B have been a limiting factor for its use, particularly at the high doses required for these infections. Recently, the in vitro and clinical activity of posaconazole, a well tolerated oral azole, has shown promising results in recent studies involving Glomeromycetes. 3 Other antifungal classes, such as echinocandins, have shown minimal in vitro activity alone against these fungi, but have demonstrated synergistic effects when used in combination with posaconazole. 4 The calcineurin inhibitors (cyclosporine A and tacrolimus) as well as the mTOR ('mammalian target of rapamycin') inhibitor (sirolimus) are routinely used for maintenance immunosuppression in solid organ and bone marrow transplant patients. 5 These drugs have shown intrinsic antifungal activity against Candida and Aspergillus species. 6 Recently we have shown a synergistic effect of azoles such as posaconazole, itraconazole and voriconazole with calcineurin inhibitors against Glomeromycetes. 7 Others have shown similar results. 8 In this study we looked at the in vitro interaction of the echinocandin caspofungin with cyclosporine A, tacrolimus and sirolimus against 26 isolates of Glomeromycetes. (4), Rhizomucor pusillus (4), Mycocladus corymbifera (3) and Apophysomyces elegans (1)] were studied by subculturing on potato flake agar. Antifungal susceptibility testing was performed according to CLSI M38-A2, 9 modified for chequerboard dilution testing using the minimum effective concentration (MEC) endpoint for caspofungin and calcineurin inhibitors/sirolimus. The MEC endpoint was taken as the lowest concentration of drug that showed significant reduction in visible growth, microscopically seen as restricted hyphal growth. In order to provide consistency, this endpoint was used both for individual drugs (caspofungin and calcineurin inhibitors/sirolimus) and for combinations, since there are no established criteria for susceptibility testing of immunosuppressant drugs. For the purposes of this article, the endpoint for immunosuppressants will be called the MIC. The final concentration for caspofungin was 0.007-8 mg/L while that for the immunosuppressants was 0.125-8 mg/L. Caspofungin in combination with calcineurin inhibitors (cyclosporine A and tacrolimus) and sirolimus was tested for in vitro interactions using a chequerboard microdilution method. Synergy was defined as a fractional inhibitory concentration index ≤0.5, indifference .0.5 to ≤4.0 and antagonism .4.0.
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Results
Caspofungin had no activity against Glomeromycetes (MEC .8 mg/L). The immunosuppressant drugs showed some intrinsic activity when used alone. Tacrolimus demonstrated the broadest activity, with MICs ≤1 mg/L for 21/26 (81%) of isolates, including at least one strain from each species tested. Cyclosporine A and sirolimus were less active, with MICs ≤1 mg/L for 7/26 (27%) and 3/26 (12%) of isolates, respectively. C. berthollettiae, Mucor sp. and R. pusillus were most consistently susceptible to immunosuppressant agents.
The combination of caspofungin with calcineurin inhibitors showed synergy in seven unique isolates and with sirolimus in seven isolates (data not shown). The drugs showed indifference in all strains of M. corymbifera and the only strain of A. elegans. No antagonism was observed in any isolate.
Despite infrequent synergy, the MEC of caspofungin was significantly lowered (.4-fold) in the presence of calcineurin inhibitors and sirolimus in 24 and 7 isolates, respectively (Table 1 ). An example of this effect is shown in Figure 1 . Interestingly, complete growth inhibition was also observed at high concentrations of caspofungin and cyclosporine A for all isolates of R. microsporus and two isolates of R. pusillus. Two isolates of Mucor showed similar inhibition at high concentrations of caspofungin and tacrolimus. All species showed lower MECs of caspofungin with calcineurin inhibitors and only R. arrhizus, Mucor sp. and R. pusillus showed lower MECs with sirolimus.
Discussion
As expected, caspofungin had no intrinsic activity against Glomeromycetes. Calcineurin inhibitors and sirolimus significantly . This is consistent with studies in other fungi demonstrating activity of calcineurin inhibitors with various antifungals. 6 Further study of this interaction is needed, as novel therapies may be developed by exploiting the effect of inhibiting the calcineurin pathway in these fungi. This is particularly relevant for mucormycosis, given the paucity of therapeutic options available to manage these infections.
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